Seebri Breezhaler gets positive CHMP opinion to treat COPD patients
Data from three of the Novartis Phase III GLOW trials, which included 1,996 COPD patients, announced the CHMP’s positive opinion for Seebri Breezhaler . Seebri Breezhaler was well
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The open-label dose-escalating trial evaluated toxicity and efficacy of perifosine, given in monotherapy to patients with neuroblastoma. Aeterna Zentaris president and CEO Juergen Engel said the data emphasise
The patent applications concern its proprietary formulation technologies for its products TX12001HR, TX12002HR and TX12003HR. TherapeuticsMD CEO Robert Finizio said, "The submission of these patents marks a new